Notice Regarding Continuation of the Performance-linked Stock Compensation Scheme and Performance-linked Stock Delivery Scheme for the Domestic and Gl5/15 11:30TDnetPDF(224KB)
Notice Regarding Continuation of the Performance-linked Stock Compensation Scheme5/15 11:30TDnetPDF(279KB)
Notice Regarding Impairment Loss and Extraordinary Losses in Non-consolidated Financial Results(J-GAAP)4/27 15:30TDnetPDF(144KB)
Astellas and Hovon Confirm Phase 3 Study Did not Meet its Primary Endpoint of Overall Survival in Patients with Newly Diagnosed FLT3m+ AML3/9 16:00TDnetPDF(184KB)
XOSPATA(ギルテリチニブ)強力な化学療法に適応のある未治療 FLT3 遺伝子変異陽性AMLを対象とした第III相PASHA試験のトップライン結果が判明3/9 16:00TDnetPDF(394KB)
Astellas Reaches Settlement Agreements with Lupin and Zydus in Myrbetriq Patent Litigation2/12 12:00TDnetPDF(147KB)